Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

November 7, 2023

Study Completion Date

February 7, 2024

Conditions
Biliary Atresia
Interventions
DRUG

Maralixibat

A small molecule inhibitor of the ileal bile acid transporter (IBAT)

OTHER

Placebo

Identical to maralixibat except for the active drug substance

Trial Locations (22)

333

Linkou Chang Gung Memorial Hospital, Taoyuan District

407

Taichung Veterans General Hospital, Taichung

10016

NYU Grossman School of Medicine, New York

10032

New York-Presbyterian - Columbia University Medical Center, New York

10467

Montefiore Medical Center, The Bronx

19104

Children's Hospital of Philadelphia, Philadelphia

30329

Children's Healthcare of Atlanta - Emory University School of Medicine, Atlanta

77030

Texas Children's Hospital, Houston

85016

Phoenix Children's Division of Gastroenterology & Hepatology, Phoenix

100020

Beijing Pediatric Research Institute, Beijing

115000

Vietnam National Children's Hospital, Hanoi

200062

Children's hospital of Shanghai, Shanghai

201102

Children's Hospital of Fudan University, Shanghai

229899

KK women's and Children's hospital, Bukit Timah

310058

The Children's Hospital, Zhejiang University School of Medicine, Hanzhou

510623

Guangzhou Women and Children's Medical Center, Guangzhou

740500

Children's Hospital No. 1, Ho Chi Minh City

Unknown

Hannover Medical School, Hanover

Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw

King's College Hospital NHS, London

Hue Central Hospital, Huế

B4 6NH

Birmingham Children's Hospital, Birmingham

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY